Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-β and Neu pathway signaling studies: Identification of a novel model for TGF-β-induced epithelial-to-mesenchymal transition

Breast Cancer Research

Volumn 6, Issue 5, 2004, Pages

  Lenferink, Anne E G ^a   Magoon, Joanne ^a   Cantin, Christiane ^a   O'Connor McCourt, Maureen D ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Epithelial to mesenchymal transition; Murine mammary epithelial cell lines; TGF

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA UROGASTRONE; NERVE CELL ADHESION MOLECULE; NEU DIFFERENTIATION FACTOR; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; MEMBRANE PROTEIN; MTVR2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; TBETAR II KINASE; TBETAR-II KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VIRUS RECEPTOR;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM CELL; BREAST TUMOR; CANCER CELL; CELL CONTACT; CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GROWTH INHIBITION; IN VITRO STUDY; MOUSE; MOUSE MAMMARY TUMOR VIRUS; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSGENE; TRANSGENIC MOUSE; ANIMAL; CELL DIFFERENTIATION; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; GENETICS; MESODERM; METABOLISM; TRANSGENIC ANIMAL; TUMOR CELL LINE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL DIFFERENTIATION; CELL LINE, TUMOR; EPITHELIAL CELLS; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE PROTEINS; MESODERM; MICE; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, ERBB-2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 4644239117     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr907     Document Type: Article

References (42)

1. Wakefield LM, Roberts AB: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev. 2002, 12: 22-29. 10.1016/S0959-437X(01)00259-3.
2. Markowitz SD, Roberts AB: Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996, 7: 93-102. 10.1016/1359-6101(96)00001-9.
3. Gobbi H, Dupont WD, Simpson JF, Plummer WD, Schuyler PA, Olson SJ, Arteaga CL, Page DL: Transforming growth factor-beta and breast cancer risk in women with mammary epithelial hyperplasia. J Natl Cancer Inst. 1999, 91: 2096-2101. 10.1093/jnci/91.24.2096.
4. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, Dupont WD, Olson SJ, Schuyler PA, Plummer WD, Page DL: Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in-situ and invasive carcinomas. Histopathology. 2000, 36: 168-177. 10.1046/j.1365-2559.2000.00841.x.
5. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL: Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest. 2002, 109: 1551-1559. 10.1172/JCI200215234.
6. Yang YA, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, Patel SC, Khozin S, Liu ZY, Green J, Anver MR, Merlino G, Wakefield LM: Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest. 2002, 109: 1607-1615. 10.1172/JCI200215333.
7. Barnard JA, Bascom CC, Lyons RM, Sipes NJ, Moses HL: Transforming growth factor beta in the control of epidermal proliferation. Am J Med Sci. 1998, 296: 159-163.
8. Dumont N, Arteaga CL: Transforming growth factor-β and breast cancer. Tumor promoting effects of transforming growth factor-β. Breast Cancer Res. 2000, 2: 125-132. 10.1186/bcr44.
9. Derynck R, Akhurst RJ, Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001, 29: 117-129. 10.1038/ng1001-117.
10. Fearon RR, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 1990, 61: 759-767. 10.1016/0092-8674(90)90186-I.
11. Reddel RR: The role of senescence and immortalization in carcinogenesis. Carcinogenesis. 2002, 21: 477-484. 10.1093/carcin/21.3.477.
12. Birchmeyer W, Behrens J, Weidner KM, Hulsken J, Birchmeier C: Epithelial differentiation and the control of metastasis in carcinomas. Curr Top Microbiol Immunol. 1996, 213: 117-135.
13. Markwald R, Eisenberg C, Eisenberg L, Trusk T, Sugi Y: Epithelial-mesenchymal transformations in early avian heart development. Acta Anat. 1996, 156: 173-186.
14. Miettinen PJ, Ebner R, Lopez AR, Derynck R: TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol. 1994, 127: 2021-2036. 10.1083/jcb.127.6.2021.
15. Oft M, Heider KH, Beug H: TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998, 8: 1243-1252. 10.1016/S0960-9822(07)00533-7.
16. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994, 331: 1286-1292. 10.1056/NEJM199411103311907.
17. Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 2000, 342: 1350-1358. 10.1056/NEJM200005043421807.
18. Portella G, Cumming SA, Liddell J, Cui W, Ireland H, Akhurst RJ, Balmain A: Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ. 1998, 9: 393-404.
19. Shi Y, Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003, 113: 685-700. 10.1016/S0092-8674(03)00432-X.
20. Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003, 425: 577-584. 10.1038/nature02006.
21. Yu L, Hebert MC, Zhang YE: TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002, 21: 3749-3759. 10.1093/emboj/cdf366.
22. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grunert S: Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol. 2002, 156: 299-313. 10.1083/jcb.200109037.
23. Grunert S, Jechlinger M, Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 2003, 4: 657-665. 10.1038/nrm1175.
24. Lenferink AEG, Magoon J, Pepin M-C, Guimond A, O'Connor-McCourt MD: Expression of TGF-β type II receptor antisense RNA impairs TGF-β1 signaling in vitro and promotes mammary gland differentiation in vivo. Int J Cancer. 2003, 107: 919-928. 10.1002/ijc.11494.
25. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R: Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ. 1998, 9: 229-238.
26. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res. 1997, 57: 5564-5570.
27. Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluoresence in situ hybridization. Oncogene. 1996, 13: 63-72.
28. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D., Geddie W, McCready D: Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol. 1998, 16: 1340-1349.
29. Ross JS, Fletcher JA: The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999, 9: 125-138. 10.1006/scbi.1998.0083.
30. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology. 2001, 61: 1-13. 10.1159/000055396.
31. Siegel PM, Shu W, Cardiff RD, Muller W, Massagúe J: Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA. 2003, 100: 8430-8435. 10.1073/pnas.0932636100.
32. Philip A, O'Connor-McCourt MD: Interaction of transforming growth factor-beta 1 with alpha 2-macroglobulin. Role in transforming growth factor-beta 1 clearance. J Biol Chem. 1991, 266: 22290-22296.
33. Pepin MC, Beauchemin M, Plamondon J, O'Connor-McCourt MD: Mapping of the ligand binding domain of the transforming growth factor beta receptor type III by deletion mutagenesis. Proc Natl Acad Sci USA. 1994, 91: 6997-7001.
34. Franzén P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, Miyazono K: Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 1993, 75: 681-692. 10.1016/0092-8674(93)90489-D.
35. Al-Moustafa AE, Urbani N, O'Connor-McCourt M: Black ink cellular spreading and motility assay. Biotechniques. 1999, 27: 60-62.
36. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P: Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell. 2003, 12: 817-828. 10.1016/S1097-2765(03)00386-1.
37. Hobbs SS, Coffing SL, Le AT, Cameron EM, Williams EE, Andrew M, Blommel EN, Hammer RP, Chang H, Riese DJ: Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene. 2002, 21: 8442-8452. 10.1038/sj.onc.1205960.
38. Vincent-Salomon A, Thiery JP: Epithelial-mesenchymal transition in breast cancer development. Breast Cancer Res. 2003, 5: 101-106. 10.1186/bcr578.
39. Hirohashi S, Kanai Y: Cell adhesion system and human cancer morphogenesis. Cancer Sci. 2003, 94: 575-581.
40. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ: N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999, 147: 631-644. 10.1083/jcb.147.3.631.
41. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000, 148: 779-790. 10.1083/jcb.148.4.779.
42. Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ, Johnson KR: N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol. 2000, 151: 1193-1206. 10.1083/jcb.151.6.1193.